I have found recent updates very interesting. It seems the fpp 1746 that has been mentioned in most updates so far as a lead candidate is pretty non specific and enters all cells "better than tat". It seems we are just now starting to find more cell specific fpp's and im guessing that will be interesting if we can indeed target certain cell types only such as heart. I guess that emphasizes the importance of the systemic in vivo cre application for q3. If i understand this correctly it refers to the ability to iv or inject fpp and then by the use of cre prove which cells it did or didnt enter. If they can show any form of targetted action it could be massive i guess.
PYC Price at posting:
3.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)